haematology

News in brief: Tecartus CAR T-cell therapy licensed for R/R MCL; Physicians stay clear of social media; Drugs for platelet-mediated thrombosis may be re-targeted for COVID-19 treatment

Tecartus CAR T-cell therapy licensed for R/R MCL The CAR T-cell therapy brexucabtagene autoleucel (Tecarta) has been licensed in Australia for use in patients with relapsed or refractory Mantle Cell Lymphoma. According to the product information approved by the TGA, the Gilead product is a CD19 directed genetically modified autologous T cell immunotherapy. A patient’s ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic